NEW YORK (GenomeWeb News) – Rosetta Genomics' stock soared 72 percent in mid-afternoon trading on Nasdaq after announcing a successful clinical study on one of its lung cancer diagnostic tests.

The Rehovot, Israel-based company's share price rose $1.33 to $3.18 from yesterday's close of $1.85.

A joint study by the company and Johns Hopkins University showed that the firm's miRview squamous non-small cell lung cancer diagnostic accurately classified NSCLC samples from resection and from fine-needle aspirate cell blocks, Rosetta said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.